CA-VERIMATRIX
21.7.2022 17:47:09 CEST | Business Wire | Press release
Regulatory News:
Verimatrix , (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that Harmonic is one of the first partners to integrate its cloud platform with Verimatrix StreamkeeperSM .
Designed to reduce streaming video service deployments from months to minutes and reaching the greatest amount of consumer devices, Streamkeeper Multi-DRM enables video service providers to securely stream with content security delivered from a highly scalable and globally redundant platform. The Streamkeeper Multi-DRM service is designed from the ground up to delivery studio endorsed best practices for content protection, with meticulous focus on ensuring superior video viewer experiences. Streamkeeper, at large, is a suite of novel and adaptive cybersecurity technologies that include and go beyond DRM to allow video service providers to manage revenue risk in a world of continuously changing threats from video piracy. It is available in multiple tiers and includes features such as Multi-DRM, a real-time performance dashboard, on-call support integrations and alerts, individual device risk scoring, anti-piracy countermeasures, and much more.
Integrating Verimatrix Streamkeeper with Harmonic’s VOS™360 cloud platform ensures customers will experience next-generation secure video streaming that harnesses the combined power of two highly-trusted industry leaders.
The Harmonic VOS360 platform makes it simple to launch and manage end-to-end video cloud workflows. Capitalizing on the company's expertise in video processing and delivery, the VOS360 platform embeds market-leading state-of-the-art microservices, including compression, packaging, origin and SSAI, in a unified software solution for next-gen cloud-based streaming. By pre-integrating the VOS360 platform with Verimatrix Streamkeeper, current and new customers can realize the combined benefits of security at scale with a rapid launch for OTT deployments on the cloud.
“We’re pleased to announce Harmonic, a cloud leader in the industry, as one of the inaugural integration partners for Streamkeeper,” said Asaf Ashkenazi , Chief Operating Officer and President at Verimatrix. “Combining innovative, proven cybersecurity and anti-piracy technologies with Harmonic’s well-known video processing and delivery platform creates a cloud-based, one-stop-shop for OTT service providers, enabling them to gain immediate business value and peace of mind for their content.”
“By integrating Verimatrix Streamkeeper with our VOS360 cloud platform, we are transforming how operators stream video,” said Shahar Bar, senior vice president, video products and corporate development at Harmonic. “Running on cloud, our solution is flexible, scalable and secure, enabling exceptional-quality streaming experiences to be delivered at scale.”
For more information about Harmonic VOS360 cloud platform, visit: https://www.harmonicinc.com/video-streaming
For more information about Verimatrix Streamkeeper, visit: www.verimatrix.com/products/streamkeeper/
About Harmonic
Harmonic, the worldwide leader in virtualized cable access and video delivery solutions, enables media companies and service providers to deliver ultra-high-quality video streaming and broadcast services to consumers globally. The company revolutionized cable access networking via the industry’s first virtualized cable access solution, enabling cable operators to more flexibly deploy gigabit internet service to consumers’ homes and mobile devices. Whether simplifying OTT video delivery via innovative cloud and software platforms, or powering the delivery of gigabit internet cable services, Harmonic is changing the way media companies and service providers monetize live and on-demand content on every screen. More information is available at www.harmonic.com
.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005490/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom